The president of the National Vaccination Committee, Maria Theodoridou, referred to key features of the new Nuvaxovid vaccine but also differences in relation to the existing vaccines for the coronary artery, during today’s briefing on the National Vaccination Coverage Plan for COVID-19 disease.
In December, the fifth vaccine in a row was licensed, which in a few days will be available in our country, reminded Ms. Theodoridou, referring to the Nuvaxovid protein vaccine.
The difference between vaccines of different technology lies in the way the immune mechanism is activated.
All vaccines in this case target the spike protein surface of the virus.
Mrna vaccines, such as Moderna and Pfizer, give genetic information and the body synthesizes the protein that causes it to produce antibodies.
Viral vaccines such as Astra Zeneca and Johnson & Johnson use a non-reproducible virus, such as the adenovirus, which safely transmits the genetic code to the body cells that produce the spike protein again.
Nuvaxovid, a laboratory-produced version of the protein spike, is given ready-made. That is, it is not produced by the body.
The technology of the vaccine is old, of the 80’s, noted Ms. Theodoridou further explaining that based on it a number of other known vaccines have been produced such as that of influenza or hepatitis.
Referring to some features of the new vaccine, Ms. Theodoridou stressed that one dose contains 5 micrograms of protein and has as an adjuvant substance a saponin Matrix M.
This is added to enable the production of more antibodies and to require a smaller amount of antigen for the preparation of vaccines, ie to be more economical.
It can be kept for 9 months at a refrigerator temperature, while as an open 10-dose bottle it can be kept at room temperature for up to six days.
Vaccine is cheap and easy to transport and is considered to make a significant contribution to vaccinations in disadvantaged countries.
It is noted that the chairwoman of the National Vaccination Committee clarified that no serious side effects have been reported and added that there is a plan to vaccinate children in two doses.
It is noted that when asked about the stage and the course of studies on the vaccines of Sanofi and Gsk, Ms. Theodoridou said that they are in phase two.
See all the news
Follow Skai.gr on Google News
and be the first to know all the news
